Form 4: Apellis CTO Sells Shares for Tax Obligations

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 7,725 shares of common stock at $21.7654 per share to cover tax withholding on restricted stock units.

Summary

• Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, Inc., reported a transaction involving the company's common stock.
• On January 22, 2026, Nicholson disposed of 7,725 shares of common stock at a price of $21.7654 per share.
• The sale was conducted to cover tax withholding obligations related to Restricted Stock Units (RSUs) that were released on January 21, 2026.
• Following this transaction, Nicholson beneficially owns 71,118 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations on vested restricted stock units, which is neutral in sentiment. It does not indicate a change in management's view of the company's prospects.

Positives

• The sale was a non-discretionary transaction to cover tax withholding, indicating it was not a sale based on a negative outlook for the company.

Negatives

• The transaction resulted in a reduction of insider ownership by 7,725 shares.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries when restricted stock units vest. It does not reflect broader industry trends or specific company performance.

Comparison to Industry Standards

• This transaction is a standard practice for executives receiving equity compensation. Many companies, such as Pfizer, Merck, or Johnson & Johnson, have executives who sell shares to cover tax obligations upon RSU vesting. The transaction itself is not comparable to specific projects or results.

Related Party Transactions

• The transaction involves an insider (Chief Technical Officer) selling company stock, which is a related party transaction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a non-discretionary reason, so minimal negative impact.
• Employees: No direct impact on employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by a Chief Technical Officer to cover tax obligations associated with the vesting of Restricted Stock Units. Such transactions are common and do not typically signal a change in the company's fundamentals or management's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Nur Nicholson, Chief Technical Officer, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Equity Compensation